Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CABA NYSE:JATT NASDAQ:PALI NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$4.15+8.4%$3.08$1.11▼$4.16$462.00M3.183.13 million shs9.23 million shsJATTJATT Acquisition$10.75-1.6%$7.06$9.99▼$11.31$83.85MN/A16,376 shs1,138 shsPALIPalisade Bio$1.97-7.5%$1.96$0.53▼$2.86$329.82M1.524.39 million shs4.59 million shsSIGASiga Technologies$4.64+0.2%$5.25$4.29▼$9.62$332.78M0.93561,954 shs366,412 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%+1.03%-0.68%+13.51%+119.40%JATTJATT Acquisition0.00%-1.32%+78.28%+89.26%+631.29%PALIPalisade Bio0.00%+1.53%+5.29%+19.88%+151.14%SIGASiga Technologies0.00%+0.88%-12.21%-33.81%-18.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCABACabaletta Bio$4.15+8.4%$3.08$1.11▼$4.16$462.00M3.183.13 million shs9.23 million shsJATTJATT Acquisition$10.75-1.6%$7.06$9.99▼$11.31$83.85MN/A16,376 shs1,138 shsPALIPalisade Bio$1.97-7.5%$1.96$0.53▼$2.86$329.82M1.524.39 million shs4.59 million shsSIGASiga Technologies$4.64+0.2%$5.25$4.29▼$9.62$332.78M0.93561,954 shs366,412 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCABACabaletta Bio0.00%+1.03%-0.68%+13.51%+119.40%JATTJATT Acquisition0.00%-1.32%+78.28%+89.26%+631.29%PALIPalisade Bio0.00%+1.53%+5.29%+19.88%+151.14%SIGASiga Technologies0.00%+0.88%-12.21%-33.81%-18.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCABACabaletta Bio 2.71Moderate Buy$17.00309.64% UpsideJATTJATT Acquisition 0.00N/AN/AN/APALIPalisade Bio 2.88Moderate Buy$10.20417.77% UpsideSIGASiga Technologies 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest JATT, PALI, CABA, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/9/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/8/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.003/26/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.003/24/2026CABACabaletta Bio GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $16.003/24/2026CABACabaletta Bio Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$14.00 ➝ $13.003/12/2026SIGASiga Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)2/25/2026PALIPalisade Bio Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/AJATTJATT AcquisitionN/AN/A$0.40 per share27.08($0.53) per shareN/APALIPalisade Bio$250K1,319.27N/AN/A$0.87 per share2.26SIGASiga Technologies$94.57M3.52$0.34 per share13.82$2.78 per share1.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCABACabaletta Bio-$167.86M-$2.28N/AN/AN/AN/A-121.73%-90.19%5/21/2026 (Estimated)JATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/APALIPalisade Bio-$16.78M-$2.12N/AN/AN/AN/A-47.76%-42.98%5/11/2026 (Estimated)SIGASiga Technologies$23.28M$0.3114.97N/AN/A24.61%11.25%9.98%5/7/2026 (Estimated)Latest JATT, PALI, CABA, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026CABACabaletta Bio-$0.41N/AN/AN/A$1.67 millionN/A5/11/2026Q1 2026PALIPalisade Bio-$0.04N/AN/AN/AN/AN/A3/23/2026Q4 2025CABACabaletta Bio-$0.45-$0.40+$0.05-$0.40N/AN/A3/10/2026Q4 2025SIGASiga TechnologiesN/A-$0.08N/A-$0.08N/A$3.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCABACabaletta BioN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ALatest JATT, PALI, CABA, and SIGA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/26/2026SIGASiga Technologiesspecial$0.604/7/20264/7/20264/23/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCABACabaletta BioN/A2.772.77JATTJATT AcquisitionN/A0.150.15PALIPalisade BioN/A28.9528.95SIGASiga TechnologiesN/A11.839.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCABACabaletta BioN/AJATTJATT Acquisition47.97%PALIPalisade Bio11.79%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipCABACabaletta Bio11.25%JATTJATT Acquisition20.00%PALIPalisade Bio0.05%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCABACabaletta Bio50111.33 million98.80 millionOptionableJATTJATT Acquisition37.80 million13.80 millionNot OptionablePALIPalisade Bio10167.42 million167.34 millionNot OptionableSIGASiga Technologies4071.72 million70.33 millionOptionableJATT, PALI, CABA, and SIGA HeadlinesRecent News About These CompaniesSIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial ResultsApril 30, 2026 | globenewswire.comInvestors Purchase High Volume of Call Options on Siga Technologies (NASDAQ:SIGA)April 30, 2026 | marketbeat.comSiga Technologies Target of Unusually High Options Trading (NASDAQ:SIGA)April 16, 2026 | marketbeat.comWhy SIGA Technologies, Inc.’s (SIGA) Stock Is Up 7.36%March 28, 2026 | aaii.comASIGA mpox therapy no longer recommended in EUMarch 27, 2026 | msn.comSiga Technologies Declares Special Dividend of 60 CentsMarch 26, 2026 | marketwatch.comSIGA Declares Special Cash Dividend of $0.60 Per ShareMarch 26, 2026 | globenewswire.comSiga Technologies (NASDAQ:SIGA) Options Surge Hits Nasdaq 100 IndexMarch 19, 2026 | kalkinemedia.comKMpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.March 17, 2026 | barrons.comA Look At SIGA Technologies (SIGA) Valuation After Weaker 2025 Earnings And Ongoing TPOXX Contract ProgressMarch 15, 2026 | finance.yahoo.comSIGA Technologies (SIGA) Is Down 9.3% After Mixed 2025 Results and New Biodefense Contract WinsMarch 15, 2026 | finance.yahoo.comSIGA Technologies Eyes TPOXX Growth As New Contracts Meet Lumpy RevenueMarch 14, 2026 | finance.yahoo.comSIGA Technologies Inc (SIGA) Q4 2025 Earnings Call Highlights: Strong Financial Performance and ...March 11, 2026 | finance.yahoo.comSIGA outlines continued TPOXX global expansion and expects EMA smallpox decision in March 2026March 10, 2026 | seekingalpha.comSIGA Technologies, Inc. (SIGA) Q4 2025 Earnings Call TranscriptMarch 10, 2026 | seekingalpha.comSIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business UpdateMarch 10, 2026 | globenewswire.comSIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial ResultsMarch 3, 2026 | globenewswire.comGeneral Atomics and Entergy Advance SiGA(R) Technology to Strengthen and Sustain US Energy SecurityFebruary 13, 2026 | finance.yahoo.comSiga Technologies (NASDAQ:SIGA) Nasdaq Top 100 Biomedical StrategyJanuary 23, 2026 | kalkinemedia.comKDiscovering Undiscovered Gems in the US Market December 2025December 29, 2025 | finance.yahoo.comSIGA's Third Quarter Results Reflect Revenue VolatilityDecember 14, 2025 | aktiencheck.deANew MarketBeat Followers Over TimeMedia Sentiment Over TimeJATT, PALI, CABA, and SIGA Company DescriptionsCabaletta Bio NASDAQ:CABA$4.15 +0.32 (+8.36%) Closing price 04:00 PM EasternExtended Trading$4.15 0.00 (0.00%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.JATT Acquisition NYSE:JATT$10.75 -0.18 (-1.65%) Closing price 02:29 PM EasternExtended Trading$10.77 +0.02 (+0.18%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Palisade Bio NASDAQ:PALI$1.97 -0.16 (-7.51%) Closing price 04:00 PM EasternExtended Trading$1.99 +0.02 (+0.96%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Siga Technologies NASDAQ:SIGA$4.64 +0.01 (+0.22%) Closing price 04:00 PM EasternExtended Trading$4.68 +0.04 (+0.86%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
